Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Posted: February 24, 2023 at 12:14 am

– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact –

Continue reading here:
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Related Posts